Futura’s business model is based on a hybrid R&D and commercial strategy, providing flexibility to develop the most appropriate commercial structure by market.
Futura has distribution or license partners in place for Eroxon® in a number of major consumer markets and we continue to seek new market opportunities with leading consumer healthcare companies to drive long-term sustainable market growth.
Futura’s business model is based on the following principles:
- Insight‑led R&D: Consumer, clinical and market insights identify unmet needs in consumer sexual health.
- Formulation science: Futura develops clinically supported topical products (Eroxon®, Eroxon® Intense, WSD4000), in its own cost-effective laboratory facility.
- Clinical regulatory and quality validation: Evidence generation and regulatory approval underpin credible claims and differentiation. ISO 13485 compliant and European MDR certified quality system.
- IP protection: Long‑dated patents (to 2040) defend products in key markets and enable value capture via partnerships.
- Hybrid commercial model: Products are commercialised through licensing or distribution partners, selected market‑by‑market with greater strategic involvement from Futura.
- Revenue generation: Monetisation via milestones, product supply, and improved per‑unit economics, reaching consumers through global retail and e‑commerce channels.
Futura’s business model is focused on a hybrid R&D and commercial approach which will provide greater flexibility, insight development and sharing and improved economic participation across markets.
Under this approach:
- Commercial structures with partners may vary and will be selected on a market‑by‑market basis
- The Group will have increased strategic input and the ability to share best commercial practice with all partners
- Knowledge and learnings can be shared more effectively across territories
- The Group can benefit more directly from commercial success, with potentially higher net margins per selling unit
- The Group will aim to reduce cost of goods through a shared global supply resource, benefiting both the Group and its partners.